Can I get vaccines while on secukinumab (Cosentyx)?
Secukinumab is a monoclonal antibody that blocks IL‑17A signaling. Because it changes immune activity, the main “contradictions” people run into are about which vaccine types are safe versus not recommended. The key rule used in clinical practice is vaccine type:
- Inactivated (non-live) vaccines: are generally considered acceptable to give during treatment.
- Live-attenuated vaccines: are usually avoided while taking secukinumab, because they contain weakened organisms that rely on a competent immune system to stay controlled.
If you’re asking because your clinic said “yes” to one vaccine but “no” to another, it’s typically because the vaccines are different in whether they are live or inactivated.
What contradictions happen with “live” versus “non-live” vaccines?
Many patients encounter mixed advice because vaccine schedules often combine multiple vaccines on the same visit, and guidance changes depending on:
- whether a vaccine is live-attenuated or inactivated,
- your treatment timing (when your last secukinumab dose was),
- your age and immune risk,
- and the condition being treated.
Examples of why advice can conflict:
- A clinician may advise against a particular live vaccine, while another vaccine on the same schedule may be inactivated and allowed.
- Some “routine” childhood recommendations use wording that people interpret as blanket permission, but the live/inactivated distinction still applies.
Do I need to stop secukinumab before a vaccine?
Whether you need to hold secukinumab depends on the vaccine type and the situation (routine prevention vs travel vs an urgent exposure). For live vaccines, standard practice is to avoid them during biologic therapy; clinicians may recommend completing the vaccine series before starting the biologic or coordinating a treatment pause only under specialist direction. For inactivated vaccines, there usually is no need to stop secukinumab, though vaccine response can vary by immune status.
Which vaccines are commonly questioned with secukinumab?
Patients often specifically worry about:
- Shingles (zoster) options: guidance depends on whether the product is live vs non-live.
- Flu shots: the regular injectable flu vaccine is typically inactivated, while the nasal spray is live-attenuated.
- MMR and varicella: these are generally live-attenuated and are the ones most likely to be contraindicated/avoided during IL‑17 blockade.
If you tell me which vaccines you’re scheduled for (name and date), I can map them to the live vs inactivated issue more precisely.
What about COVID-19 vaccines?
COVID-19 vaccines that are inactivated or non-live platform types are generally treated as compatible with biologic therapy, while any product that is live-attenuated would fall under the “avoid live vaccines” principle. Confusion often comes from how different countries used different products earlier in the rollout.
What should patients ask their prescriber to avoid conflicting advice?
To resolve contradictions, ask these practical questions at the same visit:
- “Is the vaccine live-attenuated or inactivated?”
- “If it’s live, is there a plan to give it before starting secukinumab or to delay it until after I stop?”
- “Do I need to adjust timing relative to my next secukinumab dose?”
- “Will the vaccine still work as well on IL‑17 therapy, and should I expect lower protection?”
Are there any safety red flags?
Seek urgent medical advice if you develop signs of infection after vaccination, especially fever or a rash that resembles the vaccine-target disease. Also, inform the prescriber if you have any history of serious infections, recent exposure to varicella/measles, or other immunosuppressive drugs in addition to secukinumab.
---
If you share (1) the exact vaccine names/products you’re considering and (2) your secukinumab schedule (dose and when your last/next injection is), I can give a more direct “allowed vs avoided” answer based on the live vs non-live distinction.